<DOC>
	<DOCNO>NCT01120717</DOCNO>
	<brief_summary>The study design provide long-term safety data QVA149 patient moderate severe chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>A Study Assess Long-term Safety QVA149</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male female adult age ≥40 yr Smoking history least 10 pack year Diagnosis COPD ( moderatetosevere classify Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Guidelines , 2008 ) Postbronchodilator FEV1 &lt; 80 % ≥ 30 % predict normal value postbronchodilator FEV1/FVC ( force vital capacity ) &lt; 70 % Patients respiratory tract infection within 4 week prior Visit 1 Patients concomitant pulmonary disease Patients history asthma Any patient lung cancer history lung cancer Patients history certain cardiovascular comorbid condition Patients known history diagnosis alpha1 antitrypsin deficiency Patients active phase supervise pulmonary rehabilitation program Patients contraindicate inhaled anticholinergic agent β2 agonists Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>QVA149</keyword>
	<keyword>COPD</keyword>
	<keyword>combination bronchodilator</keyword>
</DOC>